Zimmer Biomet Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
Zimmer Biomet Holdings, Inc. filed this Current Report on Form 8-K on July 30, 2015, to report its results of operations for the quarter ended June 30, 2015. The filing incorporates by reference an earnings release (Exhibit 99.1) containing detailed financial data.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It states that the company reported a net loss for the quarter ended June 30, 2015, under GAAP. Consequently, dilutive shares were excluded from the weighted average shares outstanding used to compute diluted loss per share on a GAAP basis.
Material Changes and Non-GAAP Measures
The company presents non-GAAP financial measures to exclude the effects of specific items, including:
- Inventory step-up and other inventory/manufacturing charges.
- Certain claims and special items.
- Intangible asset amortization.
- Financing and other expenses related to the Biomet merger.
- Certain tax adjustments.
- Acquisition and integration costs, asset impairment charges, employee termination benefits, and restructuring expenses.
For the quarter ended June 30, 2015, the non-GAAP adjusted diluted earnings per share calculation includes an adjustment to add back shares that would have been dilutive if the company had reported net earnings, differing from the GAAP calculation which excluded them due to the net loss.
Management Commentary and Risks
Management utilizes these non-GAAP measures internally to evaluate business performance, identify operating trends masked by one-time items, and perform trend analysis. Adjusted diluted earnings per share is also used as a performance metric in incentive compensation programs. The filing notes that these non-GAAP measures may not be comparable to similar measures reported by other companies and should not be viewed as a substitute for GAAP measures.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP financial figures, as they are not included in the 8-K text.
- Verify the reconciliation of non-GAAP adjusted net earnings and diluted earnings per share to GAAP measures.
- Confirm the specific impact of the Biomet merger expenses and restructuring charges on the quarter's results.
- Assess the magnitude of the net loss reported under GAAP for the quarter ended June 30, 2015.